| Título: | Evaluation of Renal Adverse Effects of Combination Anti-retroviral Therapy including Tenofovir in HIV-infected Patients |
| Autores: |
Tanaka, Hiroyuki; Department of Pharmacy, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, Sagamihara-city, Kanagawa, 252-0375 Arai, Mariko; Department of Pharmacy, Kitasato University East Hospital, 2-2-1 Asamizodai, Minamiku, Sagamihara, Kanagawa. Tomoda, Yoshinori; Department of Pharmacy, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, Sagamihara-city, Kanagawa, 252-0375. Wada, Tatsuhiko; Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, 1-15-1 Kitasato, Minamiku, Sagamihara, Kanagawa. Yago, Kazuo; Department of Pharmacy, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, Sagamihara-city, Kanagawa, 252-0375. Satoh, Mitsutoshi; Department of Toxicology and Pharmacology, Faculty of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi, Chiba, 274-8510 |
| Fecha: | 2013-05-13 |
| Publicador: | Journal of Pharmacy and Pharmaceutical Sciences |
| Fuente: |
 |
| Tipo: |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| Tema: | No aplica |
| Descripción: | Purpose. In order to maintain plasma HIV-RNA concentration in HIV-infected patients, below the detection limit combination anti-retroviral therapy (cART) are used. Although the nucleoside/nucleotide reverse transcriptase inhibitor, tenofovir disoproxil fumarate (TDF) is a first-line drug commonly used, it is associated with renal dysfunction. Nevertheless, only few clinical studies have focused on TDF in combination with new anti-HIV drugs, including the protease inhibitor (PI) darunavir (DRV), or the integrase strand transfer inhibitor (INSTI) raltegravir (RAL). Here we report the influence of such cART involving TDF on renal function. Methods. We retrospectively investigated 68 patients under cART that included TDF between November 2004 and May 2012. We used hospital records to establish each patient’s background and characteristics, CD4 cell count, plasma HIV-RNA concentration, drug combinations, renal function, and anti-retrovial therapy history. Results. In all patients who had received cART, the plasma HIV-RNA concentration had fallen to less than 40 copies/mL by week 24 after the start of the therapy, and an increase in the CD4 cell count was observed. For each drug used in combination with TDF, the plasma HIV-RNA concentration and CD4 cell count showed a similar trend. After week 12, the estimated glomerular filtration rate (eGFR) had significantly decreased in all patients. The eGFR was significantly lower in those received PI on week 24 and in those received INSTI on week 12. The eGFR was significantly reduced in PI group who received atazanavir + ritonavir (ATV/RTV) on week 60. The eGFR in the DRV/RTV group tended to decrease. The eGFR in the PI and ATV/RTV group was significantly lower than in the efavirenz (EFV) group on week 96. Conclusion. It selecting drugs to include in combination therapy of HIV-infected patients, consideration should be given to the risk of renal dysfunction. There is a need to monitor renal function when TDF is combined with ATV/RTV, DRV/RTV or RAL. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. |
| Idioma: | Inglés |
1 The Impact of Electronic Prescribing on the Professionalization of Community Pharmacists: A Qualitative Study of Pharmacists’ Perception por Motulsky, Aude; Université de Montréal,Winslade, Nancy; McGill University,Tamblyn, Robyn; McGill University,Sicotte, Claude; Université de Montréal | 6 Effect of Inflammation on Molecular Targets and Drug Transporters por Hanafy, Sherif; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada,El-Kadi, Ayman O.S.,Jamali, Fakhreddin; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada |
2 Statins Against Drug-Induced Nephrotoxicity por Dashti-Khavidaki, Simin; Tehran University of Medical Sciences,Moghaddas, Azadeh; Tehran University of Medical Sciences,,Heydari, Behrooz; Tehran University of Medical Sciences,,Khalili, Hossein; Tehran University of Medical Sciences,lessan-Pezeshki, Mahboob; Tehran University of Medical Sciences,,Lessan-Pezeshki, Mahbooh; Tehran University of Medical Sciences | 7 |
3 Hepatotoxic Botanicals - An Evidence-based Systematic Review por Abdualmjid, Reem J; University of Alberta,Sergi, Consolato; University of Alberta | 8 |
4 The Decrease in Farnesoid X Receptor, Pregnane X Receptor and Constitutive Androstane Receptor in the Liver after Intestinal Ischemia-Reperfusion por Ogura, Jiro,Terada, Yusuke,Tsujimoto, Takashi,Koizumi, Takahiro,Kuwayama, Kaori,Maruyama, Hajime,Fujikawa, Asuka,Takaya, Atsushi,Kobayashi, Masaki,Itagaki, Shirou,Takahashi, Natsuko,Hirano, Takeshi,Yamaguchi, Hiroaki,Iseki, Ken | 9 Functional Food and Nutraceutical Registration Processes in Japan and China: A Diffusion of Innovation Perspective por Patel, Darshika; University of Auckland,Dufour, Yvon; University of Auckland,Domigan, Neil; Auctus Limited |
5 HPLC Analysis of Mesembrine-Type Alkaloids in Sceletium Plant Material Used as An African Traditional Medicine por Patnala, Srinivas; Rhodes University,Kanfer, Isadore; Faculty of Pharmacy, Rhodes University | 10 Inhibition of Human Cytochrome P450 Metabolism by Blended Herbal Products and Vitamins por Tam, Teresa W; Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON,Akhtar, Humayoun; Guelph Food Research Centre, Agriculture and Agri-Food Canada, Guelph, ON,Arnason, John Thor; Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON,Cvijovic, Kosta; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON,Boon, Heather; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON,Cameron, D William; Faculty of Medicine, Univeristy of Ottawa, Ottawa, ON,Drouin, Cathy E; Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON,Jaeger, Walter; Department of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna,Tsuyuki, Ross T; Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB,Vohra, Sunita; CARE Program, Faculty of Medicine and School of Public Health, University of Alberta, Edmonton, AB,Foster, Brian C; Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa, ON |